[{"id":"f91ae6e4-5393-4764-b599-2b61d0792057","acronym":"","url":"https://clinicaltrials.gov/study/NCT04911166","created_at":"2021-06-02T20:57:30.562Z","updated_at":"2025-02-25T16:45:26.234Z","phase":"Phase 1","brief_title":"Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer with Progression on First-Line Immunotherapy with or Without Chemotherapy","source_id_and_acronym":"NCT04911166","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • ADV/IL-12 gene therapy"],"overall_status":"Suspended","enrollment":" Enrollment 13","initiation":"Initiation: 10/14/2021","start_date":" 10/14/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-05"}]